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Background:  The  impact  of different  cytomegalovirus  (HCMV)  glycoprotein  B  (gB)  genotypes  on patho-
genesis  remains  controversial.
Objectives:  To  investigate  the  effect  of  gB genotypes  either  as  single  infections  or as  part  of multiple
infections  on  the  early  kinetics  of  response  to  ganciclovir  therapy.
Methods:  Patients  (n = 239)  enrolled  in  a  study  of  intravenous  ganciclovir  or valganciclovir  for  the treat-
ment  of  HCMV  disease  were  analysed  by a  gB  genotype  speciﬁc  PCR  to  quantify  the amount  of  each  gB
genotype  present  at initiation  of therapy  (baseline,  day  0)  and  at days  3, 7, 14  and  21 post  therapy.
Results  and  conclusions:  In all gB  groups  (individual  gB  genotype  infections  and  mixed  genotype  infections)
there  was  a biphasic  decline  in  viral  load  after  therapy.  The  ﬁrst  phase  half life  (days  0–3)  was  ≤1  day  andolid organ transplantation was  followed  over  the  next  18  days  by  a  slower  second  phase  decline  with  half  lives  ranging  from  3.4  to
4.4 days.  The  1st  phase  rapid  decline  in  viral  load  was  dependent  upon  gB  genotype  whereas  the  ultimate
viral  load  reduction  at day  21  was  relatively  insensitive  to  gB  genotype.  A  strong  correlation  between  1st
phase decline  and  extent  of  viral  load  reduction  at  day  21  was  observed  (r  =  0.37;  p  = 0.002).  These  data
imply  that  early  reductions  in HCMV  load  after  therapy  may  be useful  in  predicting  the  duration  of  drug
l  HCMtherapy  needed  to  contro
. IntroductionHuman cytomegalovirus (HCMV) remains an important infec-
ious complication for the immunocompromised host. A range of
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direct and indirect effects have been associated with active repli-
cation (reviewed in 1, 2). Viral pathogenesis is directly related to
the degree of viral replication with a number of studies showing
viral load, and more recently cumulative load experienced during
the period of replication, are diagnostic and prognostic markers of
recurrent infection and disease.3–5 Complementary immunological
studies indicate that the quality of CD4 and CD8 T-cell responses
are critical factors in the control of high level replication.6–12
HCMV replication in vivo is highly dynamic with doubling times
of approximately 1 day13 with a basic reproductive number in liver
transplant recipients experiencing primary infection of approxi-
mately 15.14
At present, antiviral chemotherapeutic control of replication
relies upon prophylactic deployment of valganciclovir (VGCV) and
Open access under CC BY license.treatment of asymptomatic or symptomatic replication with either
intravenous ganciclovir (iv GCV) or VGCV (reviewed in 15–17).
There remains a paucity of data on the role of different HCMV
strains in pathogenesis, and their response to immune or antiviral
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ediated control. Although the prototype laboratory adapted
D169 strain was originally sequenced in 198918 and re-sequenced
ith the Towne strain more recently,19 only a limited number
f clinical strains have been subjected to full genomic sequence
nalysis.20,21 However, various genes have been subjected to more
ntense sequence analysis at a macro and micro-scale including
he surface glycoproteins B and H and UL139, UL144, UL147 and
L148.22–28 In the context of gB, four genotypes have been char-
cterized based upon RFLP analysis.29 Although gB plays a critical
ole in HCMV entry and cell-to-cell spread,30 the clinical relevance
f these gB genotypes remains controversial.31–35 At present, the
ajority of these analyses have taken place in relatively small
umbers of patients infected with a single gB genotype. How-
ver, we now know that multi-genotype infections are relatively
ommon36,37 and we reasoned that genotype speciﬁc declines in
hese mixed infections may  provide new insight into the HCMV
eplication dynamics. The recently completed VICTOR study com-
aring iv GCV and VGCV for the therapy of HCMV syndrome and
isease provided a large database of samples with frequent viral
oad sampling and a source for gB genotype analysis.38 Although
e have previously reported on the epidemiology and clinical
esponse rates with gB genotypes39 the present study undertakes
n in-depth viral kinetics analysis to investigate the potential for
ifferential decay kinetics of different gB genotypes either alone
r when in competition with other gB genotypes and to ascertain
hether early viral kinetics are associated with ultimate control of
eplication.
. Materials and methods
.1. Patient population and deﬁnitions
Solid organ transplant recipients enrolled in a randomized (1:1),
pen-label, parallel group, active drug-controlled multicentre and
on-inferiority trial comparing treatment with oral valganciclovir
o intravenous ganciclovir for the treatment of HCMV disease in
olid organ transplant recipients (ClinicalTrials.gov NCT00431353)
VICTOR study) were included as previously described.38 A total
f 321 patients received at least one dose of assigned medication
ith 164 patients randomized to treatment with 900 mg  twice daily
alganciclovir and 157 patients to 5 mg/kg twice daily i.v. gan-
iclovir included in the intention-to-treat population.38 Of these,
59 patients had conﬁrmed HCMV viremia and made up the per-
rotocol population. It is this population in which gB genotype
nalysis was performed. It is important to note that patients in
his study must have been diagnosed with HCMV disease prior to
nrolment and that initiation of antiviral therapy for HCMV was
ot based on virologic markers. Both therapeutic drug formulations
ere administered for an induction period of 21 days, followed by
00 mg  daily valganciclovir until day 49. Whole blood samples for
iral load monitoring were obtained at the start of therapy (day 0,
aseline) and at days 3, 7, 14 and 21 i.e. when patients are receiving
ull dose medication.
.2. Glycoprotein B genotyping
Quantitative genotyping of glycoprotein B was performed by
uantitative real-time PCR on DNA extracts from whole blood in all
atients at days 0, 3, 7, 14, and 21 as described in detail elsewhere.40
 mixed infection was deﬁned as HCMV infection with more than
ne gB genotype in a single sample..3. Kinetics of viral load decline
Given that the results of the VICTOR study showed no differ-
nces between the treatment arms, we combined both groups forl Virology 54 (2012) 56– 60 57
the analysis of the response of gB genotypes to therapy in either sin-
gle gB genotype or in the context of mixed gB genotype infections.
The kinetics of decline of HCMV load for each genotype within the
mixed gB infection population was analysed separately using the
mean log HCMV load at days 0, 3, 7, 14, 21. Decline rates were mod-
elled using linear regression analysis and the decline rate constant
computed using the formula:
Decline rate = ln VL(t1) − ln VL(t2)
t2 − t1
(1)
where VL is the HCMV gB genotype load at time t1 or t2 respectively.
Half lives of decline could then be computed using the following:
T1/2 =
ln 2
decline rate
(2)
Comparisons of the different rates of decline were performed
using Student’s t-test. The correlation between slope of decline and
viral load reductions from baseline to day 21 was assessed using
Spearman’s rank correlation test. All p-values <0.05 were treated
as signiﬁcant.
3. Results
3.1. Patient characteristics and baseline HCMV load in patients
with different gB genotypes
The gB genotype was determined for 239/259 of the per-
protocol patients with HCMV disease enrolled in the VICTOR study
where patients were randomized to receive either valganciclovir or
intravenous ganciclovir at full dose to control their clinical symp-
toms of HCMV infection. At the initiation of antiviral therapy (day
0, baseline), the frequency each gB genotype was  as follows: gB1
(61/239 (26%), gB2 (23/239 (10%), gB3 (24/239 (10%), gB4 (13/239
(6%) and mixed gB genotypes (118/239 (49%) [described in detail in
39]. Within the mixed infection population, the frequencies of the
combinations were as follows: gB1/gB2 (n = 19), gB1/gB3 (n = 27),
gB1/gB4 (n = 7), gB2/gB3 (n = 11), gB2/gB4 (n = 4), gB3/gB4 (n = 7), a
mixture of three gB genotypes (n = 35) and all four genotypes (n = 8).
There were no signiﬁcant differences in age, gender or antivi-
ral treatment received (intravenous GCV or VGCV), type of organ
transplanted and HCMV serostatus when stratiﬁed according to gB
genotype.
Baseline HCMV load i.e. at the initiation of treatment, in
whole blood was  highest in patients with mixed gB geno-
type infections (5.37 ± 0.92 log10 genomes/ml) compared to
individual gB genotype infections although this was only
signiﬁcant when compared with gB1 and gB2 baseline
HCMV loads (4.65 ± 0.93 log 10 genomes/ml (p = 0.0001) and
4.69 ± 0.85 log 10 genomes/ml (p = 0.002) respectively). In addi-
tion, baseline HCMV load for gB1 infections were signiﬁcantly
lower than both gB3 (5.32 ± 1.33 log10 genomes/ml; p = 0.008)
and gB4 infections (5.25 ± 0.8 log10 genomes/ml; p = 0.04). Within
the mixed gB genotype population, HCMV loads were com-
parable for gB2, gB3 and gB4 (4.65 ± 1.17 vs 4.64 ± 1.18 vs
4.59 ± 0.89 log10 genomes/ml respectively) but gB1 HCMV loads
(4.27 ± 1.17 log10 genomes/ml) were signiﬁcantly lower (p = 0.05).
3.2. Decay kinetics of gB genotype load in mixed and single
infections after initiation of therapy
Initially we investigated the decay kinetics of HCMV in patients
with only mixed gB genotype infection (n = 118) for both total
HCMV load and for individual gB genotypes within the patients
with mixed genotype infections. The decay kinetics for the total
HCMV load followed a biphasic decline with an initial phase from
days 0 to 3 having a half life of approximately 0.79 days and a
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Table 1
Biphasic decline parameters for each gB genotype in patients with mixed gB genotype infections.
Genotype (n) Baseline HCMV load (log10 genomes/ml) 1st phase half life of decline (days) 2nd phase half life of decline (days)
gB1 (n = 61) 4.65 ± 0.95 1.04 ± 0.81 3.66 ± 2.28
gB2  (n = 23) 4.69 ± 0.85 0.65
gB3  (n = 24) 5.32 ± 1.33 0.94
gB4  (n = 13) 5.25 ± 0.92 0.65
Fig. 1. Decline in HCMV load in whole blood of patients with mixed gB genotype
infections following receipt of ganciclovir therapy. The mean of each dataset at days
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c,  3, 7, 14 and 21 were used to produce an average viral load at each time point (±1
D) and a biphasic curve ﬁt use to identify the mean rate of decline between days
–3 and 3–21.
lower 2nd phase decline between days 3 and 21 of 4.11 days
Fig. 1). Individual 1st and 2nd phase kinetics for each gB geno-
ype differed within this mixed gB genotype population (Table 1).
B genotype 1 was associated with the slowest 1st phase decline
1.04 days) which was signiﬁcant for the comparison between gB1
nd gB2/gB4 (p = 0.03 and 0.015 respectively). In addition, both gB2
nd gB4 1st phase half lives were signiﬁcantly more rapid than the
B3 1st phase half life (p = 0.01 for both comparisons). In contrast to
hese differences, the 2nd phase decline rates were more compara-
le with half lives of approximately 3.5 days with only a signiﬁcant
ifference observed between the 2nd phase decline of gB2 and gB3
nfections (p = 0.04).
In order to place these individual gB genotype decay kinetics
ithin the mixed gB genotype population in context, we assessed
he HCMV decay kinetics of patients with single gB genotype infec-
ions (n = 121). Consistent with our observations for the mixed gB
enotype decay kinetics, single gB genotype infections followed a
iphasic decline with a 1st phase half life of approximately 1 day
nd a second phase decline rate of between 3.5 and 5 days (Table 2).
omparison of the 1st and 2nd phase half lives between patients
ith single gB genotype infections and mixed infection revealed
hat the 1st phase half life for all mixed infections were signiﬁcantly
aster compared to gB1 (difference = 0.38 days (95% CI 0.08–0.67);
able 2
iphasic decline parameters for single gB genotype infections and cumulatively for pati
ompared with the gB genotype declines rates in the patients with mixed infections show
Genotype Baseline HCNV load
(log10 genomes/ml)
gB1 4.27 ± 1.17 
gB2 4.65 ± 1.15 
gB3 4.64 ±  1.18 
gB4  4.59 ± 0.89 
Mixed  infection 5.37 ± 0.92 ± 0.27 4.36 ± 3.31
 ± 1.0 3.46 ± 2.39
 ± 0.35 3.40 ± 1.86
p = 0.013), gB3 (difference 0.38 days (95% CI 0.04–0.71); p = 0.028)
and gB4 (difference = 0.4 days (95% CI 0.05–0.75); p = 0.025). In con-
trast, there were no signiﬁcant differences in the 2nd phase decline
between single gB genotype infections and the mixed infection
group.
3.3. Correlation between decay kinetics and replicative control at
day 21
We  next investigated whether the 1st phase decline kinetics of
HCMV in whole blood after initiation of therapy was  associated
with either the 2nd phase decline rate or the absolute reduction in
HCMV load by day 21 of therapy. There was no correlation between
1st and 2nd phase decline rates in any groups (mixed gB genotypes
or single gB genotype patients). In contrast, there was a signiﬁcant
correlation between 1st phase decline rates and the log reduction
in HCMV load between day 0 and day 21 in patients with mixed
gB genotype infection (Spearman’s r = 0.37; p = 0.002) or when the
single gB genotype infections were combined (Spearman’s r = 0.35;
p = 0.0004; Fig. 2). When the individual gB genotypes were ana-
lysed separately the 1st phase decline in gB1, gB2 and gB4 infections
was  signiﬁcantly correlated with the log decline at day 21 (r = 0.32
(p = 0.02); r = 0.45 (p = 0.04); r = 0.67 (p = 0.02) respectively) whereas
the same analysis for gB3 failed to reach statistical signiﬁcance
(r = 0.22; p = 0.28).
4. Discussion
To date there have been relatively few large scale analyses of the
in vivo effect of antiviral therapy on different HCMV strains. In the
present study we  show that subtle differences in the early kinet-
ics of response to antiviral chemotherapy are apparent between
different gB genotypes and in patients with mixed gB genotype
infections. However, after 21 days of therapy these differences were
insigniﬁcant i.e. gB genotype appears not to inﬂuence the ultimate
control of replication after ganciclovir therapy. An important obser-
vation in our study was that HCMV load in whole blood appears to
follow a bi-phasic decline with an initial half life of <1 day and a
second phase half life of about 4 days. This biphasic decline has
been recently been described in a single case report of a stem cell
transplant recipient after artesunate therapy.41 Previous work in
HIV-infected HCMV retinitis patients where HCMV load was  in
a quasi-steady state has shown that HCMV replication is highly
dynamic with half life of decline averaging 1 day.13,14 Thus, the ﬁrst
phase decline observed in our present study would be consistent
with this data.
ents with mixed gB genotype infections. These decline rates for gB 1–4 should be
n in Table 1.
1st phase half live of
decline (days)
(number, n)
2nd phase half life of
decline (days)
(number, n)
1.17 ± 1.31 (n = 56) 4.27 ± 2.77 (n = 47)
0.92 ± 0.78 (n = 20) 3.62 ± 2.83 (n = 19)
1.17 ± 1.36 (n = 23) 5.25 ± 3.96 (n = 22)
1.19 ± 1.09 (n = 12) 5.08 ± 3.34 (n = 10)
0.79 ± 0.67 (n = 87) 3.84 ± 3.28 (n = 81)
V.C. Emery et al. / Journal of Clinica
Fig. 2. Relationship between the ﬁrst phase decline half life and log reduction in
HCMV load attained at day 21 of therapy. The data are shown for patients with mixed
gB  genotype infection (panel A, n = 118) and for patients with single gB genotype
infections (panel B). Individual gB genotypes in panel B are identiﬁed by the colour
of  the marker (gB1 (n = 42) = black; gB2 (n = 20) = blue; gB3 (n = 23) = green and gB4
(n  = 12) = red). The Spearman’s rank correlation coefﬁcient of the data in panel A was
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1.37  (p = 0.002) and for the data in panel B was 0.35 (p = 0.0004). (For interpretation
f  the references to colour in this ﬁgure legend, the reader is referred to the web
ersion of the article.)
Exploration of the factors associated with the different decline
ates and ultimate control of replication i.e. baseline viral load
n individual or mixed gB genotype infections, the relationship
etween 1st and 2nd phase declines etc. did not reveal any sig-
iﬁcant associations. However, there was a signiﬁcant association
etween the half life of the 1st phase decline and the ultimate log
eduction in HCMV load attained at day 21 of therapy in patient
ith mixed gB genotype infections and when all single gB geno-
ype infected patients were combined. To our knowledge this is the
rst report of an association between very early viral load kinetics
fter anti-HCMV therapy and the ultimate antiviral control of HCMV
eplication at later times. These observations are consistent with
ata for both HIV and HCV treatments indicating that the very early
iral kinetics provide important prognostic information for ulti-
ate replication control and sustained virological response.42–44
n addition, it has been reported previously that higher viral loads
t baseline are a risk factor for failure to control CMV  replication
elow detectable levels in patients included in the present study
nd that patients with mixed gB genotype infections have higher
aseline viral loads.39
It is unclear why polymorphisms in the gB gene might be asso-
iated with differences in antiviral response. Although gB plays
mportant roles in viral binding and entry to cells30 it is pos-
ible that it may  be a surrogate marker for other genetic traits
.e. gB genotypes are in linkage disequilibrium with distinct DNA
olymerase genotypes that are associated with more or less replica-
ion competent viruses especially since the polymerase is adjacent
o gB on the HCMV genome. This could account for the differ-
nces seen in our study within individual gB genotype populations.
lthough superinfection with a new strain would be facilitated
y the immune evasion genes of the incoming HCMV strain45
1l Virology 54 (2012) 56– 60 59
we  do not think that this has a major inﬂuence on response to
therapy and in other studies, serostatus has not been associated
with different decline rates.46 However, the interaction between
gB genotypes during a mixed infection including competition and
relative ﬁtness differences may  also contribute to our observations.
In order to disentangle this area, whole genome sequencing, or
deep sequencing47 of the HCMV strains present in these patients
will be informative and should further enhance our knowledge of
the genetic ﬂuidity of pathogenic strains of HCMV and allow more
sophisticated dynamic models of HCMV replication to be devel-
oped.
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